Results 91 to 100 of about 76,116 (300)

Resection margin influences survival after pancreatoduodenectomy for distal cholangiocarcinoma

, 2017
Introduction: Distal cholangiocarcinoma remains a rare cancer associated with a dismal outcome. There is a lack of effective treatment options and where disease is amendable to resection, surgery affords the best potential for long-term survival. The aim
Sheen, A, Samra, JS, Mittal, A, Arena, J, Gill, AJ, Chua, TC   +5 more
core   +1 more source

Novel Targeted Therapies for Advanced Cholangiocarcinoma

, 2021
Cholangiocarcinoma (CCA) includes a group of rare and aggressive hepatobiliary malignancies, including extrahepatic cholangiocarcinoma (eCCA) and intrahepatic cholangiocarcinoma (iCCA), with the former further subdivided into distal (dCCA) and perihilar ...
Giovanni Brandi, Alessandro Rizzo
core   +1 more source

SOX30 Facilitates Triple‐Negative Breast Cancer Metastasis via TNFR2–NF‐κB Signaling and Tumor Microenvironment Remodeling

Advanced Science, EarlyView.
SOX30 drives triple‐negative breast cancer (TNBC) metastasis through a dual mechanism: direct activation of the TNFR2/NF‐κB signaling cascade and subsequent CCL20‐mediated recruitment of tumor‐associated macrophages (TAMs) into the tumor microenvironment.
Pingping Gao, Na Sun, Ning Yang, Tingting Zhao, Rui Fu, Zhenyu Wu, Yuqin Zhou, Xuanni Tan, Yi Zhang, Fei Han, Xiaowei Qi   +10 more
wiley   +1 more source

Descriptive epidemiology of cholangiocarcinoma in Italy

, 2010
BACKGROUND: Very little data exist on the epidemiology of cholangiocarcinoma in Italy. AIM: We focus on the descriptive epidemiology of cholangiocarcinoma in Italy.
Alvaro D, Crocetti E, FERRETTI, Stefano, Bragazzi MC, Capocaccia R, AISF Cholangiocarcinoma committee   +5 more
core  

Accelerating Primary Screening of USP8 Inhibitors from Drug Repurposing Databases with Tree‐Based Machine Learning

Advanced Intelligent Discovery, EarlyView.
This study introduces a tree‐based machine learning approach to accelerate USP8 inhibitor discovery. The best‐performing model identified 100 high‐confidence repurposable compounds, half already approved or in clinical trials, and uncovered novel scaffolds not previously studied. These findings offer a solid foundation for rapid experimental follow‐up,
Yik Kwong Ng, Sharon Ai Er Lam, Wei Chun Lim, Hannah Hui Min Toh, Shi Jun Ang   +4 more
wiley   +1 more source

Anticholangiocarcinoma activity and toxicity of the Kaempferia galanga Linn. Rhizome ethanolic extract

BMC Complementary and Alternative Medicine, 2017
Background Cholangiocarcinoma (CCA) is an important public health problem in several tropical and subtropical parts of the world particularly Thailand.
Asmare Amuamuta, Tullayakorn Plengsuriyakarn, Kesara Na-Bangchang   +2 more
doaj   +1 more source

Using Synthetic Glycans to Investigate Anti‐Glycan Antibodies and Explore Their Medical Potential

Angewandte Chemie International Edition, EarlyView.
Anti‐glycan antibodies are essential in health and disease. Access to novel glycan structures paves the way for progress in antibody profiling for biomarker discovery, antibody development, and vaccine design. We summarize the strategies to synthesize and utilize synthetic glycans for the development and application of anti‐glycan antibodies in basic ...
Fabienne Weber, Aina Valenti, Jiří Ledvinka, Oren Moscovitz, Peter H. Seeberger   +4 more
wiley   +1 more source

Perioperative and long-term outcome of intrahepatic cholangiocarcinoma involving the hepatic hilus after curative-intent resection: comparison with peripheral intrahepatic cholangiocarcinoma and hilar cholangiocarcinoma

, 2018
Background: Intrahepatic cholangiocarcinoma with hepatic hilus involvement has been either classified as intrahepatic cholangiocarcinoma or hilar cholangiocarcinoma.
Luca Aldrighetti, Feng Shen, Aldrighetti, Luca, Maithel, SK, Koerkamp, B Groot, Timothy M. Pawlik, Popescu, Irinel, Yi Lv, Lv, Yi, Soubrane, O, Weiss, M, Poultsides, George A, Groot Koerkamp, B; id_orcid, Poultsides, GA, Xu-Feng Zhang, Zhang, XF, Qinyu Chen, Carlo Pulitano, Weiss, Matthew, Martel, Guillaume, Beal, EW, Lv, Y, Guglielmi, Alfredo, Pulitano, C, Pawlik, Timothy M, Fabio Bagante, Bagante, F, Martel, G, Guglielmi, A, Popescu, I, Maithel, Shishir K, Bagante, Fabio, Olivier Soubrane, Bauer, Todd W, Marques, Hugo P, Soubrane, Olivier, Aldrighetti, L, B. Groot Koerkamp, Beal, Eliza W, Guillaume Martel, Eliza W. Beal, Alfredo Guglielmi, Itaru, Endo, Pawlik, TM, Groot Koerkamp, B, Irinel Popescu, Shen, F, Zhang, Xu-Feng, Pulitano, Carlo, Shen, Feng, George A. Poultsides, Itaru, E, Chen, Qinyu, Hugo P. Marques, Shishir K. Maithel, Todd W. Bauer, Chen, QY, Marques, HP, Bauer, TW, Matthew Weiss, Endo Itaru   +60 more
core   +2 more sources

Photodynamic therapy for cholangiocarcinoma: overview and new developments

, 2009
PURPOSE OF REVIEW: Photodynamic therapy (PDT) with hematoporphyrins has emerged as promising treatment for nonresectable cholangiocarcinoma in several prospective observational studies and two randomized studies.
Ortner, Maria-Anna
core   +1 more source

Status of oncology drugs with a conditional approval: A cross‐sectional comparison of the Food and Drug Administration and Health Canada

British Journal of Clinical Pharmacology, EarlyView.
Aims This study looks at the status of the same drugs conditionally approved by the Food and Drug Administration and Health Canada for the same oncology indication. Methods Lists of oncology drugs with a conditional approval from the Food and Drug Administration and Health Canada were generated and drug pairs with the same indication were matched ...
Joel Lexchin
wiley   +1 more source